Clinical Superiority and Natural Restoration of Upper Airway Patency
The top-line Phase 3 clinical data presented by Eli Lilly provides compelling scientific validation for patients burdened by chronic obstructive sleep apnea (OSA). Over the comprehensive 52-week evaluation period, patients administered the daily oral tablet Foundayo experienced an average reduction of up to 44% in recurring hypoxic breathing interruptions, underscoring fundamental structural and functional improvements.
This dramatic therapeutic effect confirms that targeted pharmacological reduction of pharyngeal adiposity directly alleviates nocturnal airway collapse, restoring vital nocturnal blood oxygen saturation without relying upon invasive surgical interventions or mechanical continuous positive airway pressure devices.
*“Foundayo reduced breathing interruptions by up to 44% on average at 52 weeks as measured by a diagnostic scale used to measure the severity of sleep apnea.” Eli Lilly and Company*
The Oral Formulation Revolution Challenging Injectable Dominance
The clinical triumph of Foundayo represents a monumental paradigm shift in pharmaceutical engineering, successfully transitioning advanced metabolic mechanisms from weekly injectable pens into a shelf-stable oral tablet. Historically, injectable therapies encountered notable challenges regarding needle aversion, complex supply chain cold-storage requirements, and long-term patient compliance friction.

















